LITTLE CANADA, Minnesota — St. Jude Medical Inc. (NYSE:STJ) won European approval to begin selling its Trifecta valve, which is designed to replace a patient’s damaged aortic valve.
Replacement Heart Valves
ATS Medical trims net loss by 68 percent in 2009
ATS Medical Inc. (NSDQ:ATSI) reported sales of $18.7 million during the fourth quarter, an increase of 4 percent when compared to the $18 million the company reported during the same period in 2008.
The Minneapolis, Minn.-based heart valve repair products company managed to trim its net loss to $3.4 million for the three months ended Dec. 31, 2009, a 62 percent decrease from the $8.5 million the company lost during the same period last year.
For the year, ATS managed to narrow its net losses by 68 percent, reporting a loss of just over $6 million on $75 million in sales, compared to a $19 million loss on $66 million in sales during 2008.
FDA OKs Medtronic device for congenital heart disease
By Thomas Lee
FRIDLEY, Minnesota- The Food & Drug Administration approved a new type of arterial valve designed for patients, mostly young children, suffering from congenital heart disease made by Medtronic Inc. (NYSE:MDT).
ATS Medical reports first commercial use of sutureless aortic valve
MINNEAPOLIS, Minnesota — Cardiology device maker ATS Medical Inc. (NSDQ:ATSI) announced the completion of the first commercial implants of its recently cleared sutureless aortic valve.
CardiAQ Valve drums up $6.5 million in Series A round
Barely four months after being named to the board of CardiAQ Valve Technologies, Robrecht “Rob” Michiels led a group of angel investors in a $6.5 million boon for the Winchester, Mass.-based start-up.
Viacor co-founder, Cleveland Clinic doc joins Endovalve board
A prominent Ohio cardiologist with ties to Massachusetts is joining the board of Endovalve, a New Jersey-based mitral valve repair firm, MedCity News reported.
Marc Gillinov, head of the Cleveland Clinic’s Center for Atrial Fibrillation and a co-founder of Wilmington, Mass.-based Viacor, was named to Endovalve’s scientific advisory board.